Presented by

Jolene J Bierly, MSFS, D-ABFT-FT

Author

Jolene J Bierly, MSFS, D-ABFT-FT

Where is it presented

AAFS

Date

February 2023

Summary

To aid in interpretation of PM blood concentrations of donepezil (Aricept), a drug approved for the treatment of Alzheimer’s disease, this poster evaluated blood specimens (antemortem and postmortem) submitted during death investigations. Approximately, 76% of postmortem blood concentrations exceeded the recommended therapeutic range for donepezil. Postmortem redistribution was further evaluated using paired blood specimens and case histories. Postmortem donepezil concentrations should be interpreted with caution in the context of a comprehensive case history.

Request a Copy

Request a PDF copy of the poster by completing the information below.